

ASX ANNOUNCEMENT

15 August 2024

Notice of FY24 Full Year Results and Investor Webinar

EZZ Life Science Holdings Limited (ASX: EZZ) ("EZZ" or the "Company") will release its preliminary FY24 unaudited financial report on Wednesday, 28 August 2024.

Following the results release, EZZ's Chair Mr Glenn Cross and CFO Mr Tony Guarna will host an investor webinar at 14:00 AEST on Wednesday, 28 August 2024.

To register for the webinar, please use the following link: https://us06web.zoom.us/webinar/register/WN ZjVeAMNLRNqhXoL-WYTbVQ

Registered attendees will receive an email with details on how to join the webinar. Participants will be able to submit questions during the webinar via the 'submit question' facility displayed on screen or can submit them in advance to ir@ezzlife.com.au.

This announcement was authorised for release by the Board of EZZ Life Science Holdings Ltd.

ENDS

For further information, please contact:

Investors

https://www.ezzlife.com.au/investors ir@ezzlife.com.au

Media

James Hudson +61 467 761 166 james.hudson@ezzlife.com.au

About EZZ Life Science

EZZ Life Science Holdings Limited (ASX:EZZ) is an Australian genomic life science company with a mission to improve quality of life and human health. EZZ Life Science has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), children's health, and weight management. EZZ Life Science is passionate about investing in the future of consumer health through the development of e-commerce and distribution of high-quality products via omnichannel models across Australia, New Zealand, China and worldwide. EZZ Life Science is led by an experienced senior management team that have implemented strategies to drive rapid and ongoing growth of the business.

For more information please visit our corporate site $\underline{\text{ezzlife.com.au}}$ and our consumer site $\underline{\text{ezzdna.com.au}}$.